Abbott Laboratories (ABT) said that its new leadless pacemaker system met primary endpoints in pivotal trial.
The company noted that the new, late-breaking data from the Leadless II IDE study confirmed the company's investigational Aveir leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms.
Abbott noted that its Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed. The leadless pacemaker is currently being evaluated for the FDA approval.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.